RT Journal Article
SR Electronic
T1 Impact of vaccination on the COVID-19 pandemic: Evidence from U.S. states
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.08.21256892
DO 10.1101/2021.05.08.21256892
A1 Chen, Xiao
A1 Huang, Hanwei
A1 Ju, Jiandong
A1 Sun, Ruoyan
A1 Zhang, Jialiang
YR 2021
UL http://medrxiv.org/content/early/2021/05/12/2021.05.08.21256892.abstract
AB Governments worldwide are implementing mass vaccination programs in an effort to end the novel coronavirus (COVID-19) pandemic. Although the approved vaccines exhibited high efficacies in randomized controlled trials1,2, their population effectiveness in the real world remains less clear, thus casting uncertainty over the prospects for herd immunity. In this study, we evaluated the effectiveness of the COVID-19 vaccination program and predicted the path to herd immunity in the U.S. Using data from 12 October 2020 to 7 March 2021, we estimated that vaccination reduced the total number of new cases by 4.4 million (from 33.0 to 28.6 million), prevented approximately 0.12 million hospitalizations (from 0.89 to 0.78 million), and decreased the population infection rate by 1.34 percentage points (from 10.10% to 8.76%). We then built a Susceptible-Infected-Recovered (SIR) model with vaccination to predict herd immunity. Our model predicts that if the average vaccination pace between January and early March 2021 (2.08 doses per 100 people per week) is maintained, the U.S. can achieve herd immunity by the last week of July 2021, with a cumulative vaccination coverage of 60.2%. Herd immunity could be achieved earlier with a faster vaccination pace, lower vaccine hesitancy, or higher vaccine effectiveness. These findings improve our understanding of the impact of COVID-19 vaccines and can inform future public health policies regarding vaccination, especially in countries with ongoing vaccination programs.Competing Interest StatementThe authors have declared no competing interest.Funding StatementH.H. is supported by the startup grant from the City University of Hong Kong (grant no. 7200689).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Our study use publicly available data, including statistics published by the government and collected from open-sourced platforms.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets and code used for the analyses are available at https://github.com/huntabaobao007/US-COVID-19-vaccination. https://github.com/huntabaobao007/US-COVID-19-vaccination